HER2-positive breast cancer, one of the most aggressive forms of this disease, presents significant therapeutic challenges due to its complexity and high recurrence. Subcutaneous therapies, such as trastuzumab and pertuzumab, have improved treatment efficacy and patient quality of life, but pose challenges for nursing professionals in patient education, prevention of complications, and use of remote monitoring technologies. This study reviewed literature from 2015 to 2024 in databases such as PubMed, Scopus, APA PsycNet, Scielo, and Web of Science to analyze advances in the management of subcutaneous therapies and nursing care. The findings confirm that subcutaneous administration of trastuzumab and pertuzumab is safe and well tolerated, reducing complications compared to traditional methods, especially when using devices such as PICC catheters and subcutaneous ports. The integration of telemedicine and remote monitoring allowed for improved adherence, minimized complications, and optimized resources. Furthermore, ongoing training of nursing staff was identified as essential for effective management of devices and fostering patient autonomy. This review underlines the importance of integrating technologies and education into public health policies to address emerging issues in breast cancer management, especially in vulnerable populations with limited access to services. This review was registered in the Open Science Framework (OSF). (Registration number: DOI: 10.17605/OSF.IO/KWPC9)
